Marktlink → Sectors → Science & Health

  • Updated March 5, 2026

Where innovation meets patient impact

Science & Health is the highest-valued sector in multiple European markets. From biotech pipeline deals to medtech regulatory arbitrage, from healthcare PE roll-ups to pharmaceutical patent cliff acquisitions — buyers pay premiums for innovation, regulatory moats, and patient outcome data.

Sector at a Glance

Overall Valuation Range

0.0x – 0.0x

↑ +0.6x vs 2024

EBITDA Multiple
Deals in 2025

0

Active Buyers

0+

4 subsectors • Click below for detailed analysis

Explore Subsectors

Each subsector has its own valuation logic, buyer landscape, and growth dynamics.

Biotechnology

[XX] deals in 2025

+0.0x

Multiple Range

0.0x – 0.0x

Average

0.0x

Key Insight

Biotech valuation is the most complex in M&A. A commercial-stage biotech with approved products trades at 7-10x EBITDA. IP and pipeline stage define the valuation spectrum.

Pipeline-stage dependent valuation
Strategic pharma acquiring to offset patent cliffs
AI-driven drug discovery premium emerging

Strategic 55% • PE 25% • International 15%

Healthcare

[XX] deals in 2025

0.0x

Multiple Range

0.0x – 0.0x

Average

0.0x

Key Insight

Healthcare is the most recession-proof and increasingly competitive M&A sector. Recurring revenue and specialization drive premiums.

Highest sector multiple in CEE and Southern Europe
PE roll-ups in specialty care and home health
Digital health integration premium

Strategic 45% • PE 35% • International 12%

Medtech

[XX] deals in 2025

+0.0x

Multiple Range

0.0x – 0.0x

Average

0.0x

Key Insight

Medtech M&A is driven by two forces: innovation premium and regulatory moat. Regulatory compliance and innovation create buyer urgency.

MDR/IVDR compliance as acquisition catalyst
Cross-border filings up 25% YoY in Europe
Innovation in cardio, neuro, and imaging commands premiums

Strategic 55% • PE 25% • International 15%

Pharmaceuticals

[XX] deals in 2025

+0.0x

Multiple Range

0.0x – 0.0x

Average

0.0x

Key Insight

Pharmaceutical M&A is driven by patent cliff urgency and manufacturing capacity scarcity.  Patent cliffs and CDMO demand reshape the landscape.

Patent cliff urgency drives strategic M&A
CDMO/CMO outsourcing premium
Specialty pharma outperforms generics

Strategic 55% • PE 25% • International 15%

Why Marktlink in “Science & Health”

IP & Regulatory Moats

Patents, CE marks, and clinical data create barriers to entry that buyers pay significant premiums for.

Resilient Demand

Healthcare spending grows regardless of economic cycles, providing revenue predictability that investors value.

Cross-Border Activity

Cross-border filings in Europe up 25%+ YoY. Global pharma and medtech groups actively acquiring European assets.

AI & Digital Integration

AI-driven drug discovery, diagnostic AI, and digital health platforms command the fastest-growing premiums.

What This Means for You

Interactive tools that give you immediate insights—or full reports in your personal portal.

30 sec

Marktlink Multiple

Your estimated valuation

Direct: Indicative multiple

Portal: Detailed range + comparable deals
+ factors breakdown

30 sec

BuyersChecker

How many buyers match you

Direct: Number of matches

Portal: Buyer profiles + alerts when
new buyers match

30 sec

Benchmark Tool

Your performance vs sector

Direct: Position indication

Portal: Full benchmark report
+ quarterly updates

30 sec

Buyer Appeal Scan

Which buyers want you

Direct: Top buyer type

Portal: All buyer types ranked + appeal factors
+ matching profiles

1 min

Timing Scan

Market timing analysis

Direct: Timing score

Portal: Detailed timing report
+ market alerts

2 min

Sale Readiness Test

How prepared are you

Direct: Readiness score

Portal: Full assessment
+ personalized action plan